A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
SWOG

Protocol Number
SWOG S1404

To Learn More Call
201-510-0910